Putting Science To Work For Patients ASN Kidney Week 2026

“There is a persistent unmet need for additional treatment options for IgA nephropathy (IgAN) and primary membranous nephropathy (pMN), as many patients continue to progress despite currently available therapies. At Vertex, we are committed to addressing the underlying immune drivers of IgAN and pMN and delivering meaningful outcomes for patients living with these chronic, progressive diseases. We strive to meet the kidney community where they are, from listening to lived experiences that may evolve how we treat and measure disease, to helping patients and care teams better understand the markers that matter most, including proteinuria – we aim to help people navigate their disease with greater clarity and work toward a future that isn’t solely defined by kidney decline.”

“Too many people are living with kidney disease without knowing there could be an underlying genetic cause. The cause of APOL1-mediated kidney disease, or AMKD, was only discovered in 2010 and there are no approved treatments for the condition, which occurs in people of African ancestry. At Vertex, we are committed to increasing awareness of AMKD. We partner closely with the AMKD community to help people have more informed conversations with their doctors about the cause of their disease.”

“Renal medicine has entered a new era defined by momentum and hope for patients. Our teams at Vertex are excited to be at the leading edge of an incredible wave of research and development, working hard each day to ensure people living with serious kidney diseases, including IgAN, AMKD and autosomal dominant polycystic kidney disease (ADPKD), can benefit from innovations in care and the potentially transformative therapies on the horizon."

“There is real progress underway in kidney medicine and a growing sense that we can rethink how serious kidney diseases are approached, studied, and treated. At Vertex, we are proud to be advancing targeted approaches to several kidney diseases, including IgAN and AMKD, among others – harnessing our deep understanding of causal human biology to target disease progression and potentially redefine the patient experience across the renal space."

"IgAN remains a serious and progressive kidney disease that can have a profound impact on patients’ lives. At Vertex, our goal is to bring forward therapies that can meaningfully improve outcomes for people living with IgAN. At this year’s ASN Kidney Week, we look forward to deepening our understanding of patient and physician needs in the diagnosis and management of IgAN. We are also proud to share our latest clinical data and real-world insights on patient perceptions of treatment options."

"Real progress for people living with kidney diseases depends on incorporating patient voices and lived experiences in every stage of our work. We're committed to partnering directly with the patient community, listening closely to their needs and building those insights into our approach from day one. That's how we turn scientific ambition into meaningful outcomes."